For example, PARP inhibitors, such as olaparib, cause vasodilation and increase tumor perfusion, effectively ameliorating hypoxia and areas of resistance to radiation within the tumor, thereby enhancing tumor sensitivity to radiation (178). Here, PARP1 is linked to neoplasm.